| Similar Articles |
|---|
 |
The Motley Fool
December 10, 2010
Brian Orelli |
Was This Drug Destined for Failure? Pfizer announces that it's pulling Thelin off the market, and withdrawing the marketing application with the Food and Drug Administration, because a new side effect was discovered.   |
The Motley Fool
June 5, 2008
Brian Lawler |
Allergan Lashes Out The pharmaceutical announces a new drug that could promote eyelash growth. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
Chemistry World
June 10, 2008
James Mitchell Crow |
A Drug for Longer Lashes? US drugmaker Allergan, the California-based company that makes antiwrinkle treatment Botox, has developed a new cosmetic drug that makes eyelashes grow longer, thicker and darker. |
The Motley Fool
November 5, 2010
Brian Orelli |
Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta. |
The Motley Fool
April 6, 2011
Brian Orelli |
Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
October 7, 2009
Jim Mueller |
Daily Walk of Shame: Money-Hungry Drugmakers If Allergan wins its suit against the government, consumers will really be in trouble. |
The Motley Fool
January 28, 2008
Brian Lawler |
Can Encysive Catch the Competition? After two years of spectacular mismanagement, will 2008 be the year that Encysive Pharmaceuticals is finally able to capitalize on its very marketable lead drug, Thelin? |
The Motley Fool
May 14, 2008
Brian Lawler |
Teaching Old Drugs New Tricks Pfizer's top drugs post mixed results in recent off-label studies. |
The Motley Fool
April 22, 2011
Sean Williams |
Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings. |
The Motley Fool
September 12, 2008
Brian Lawler |
A New Wrinkle for an Old Drug Allergan's muscle relaxant Botox performs well in two studies testing its ability to prevent migraine headaches. |
Chemistry World
June 24, 2015
Matthew Gunther |
Allergan to buy out Kythera Biopharma for $2.1bn The pharma firm Allergan will acquire Kythera Biopharmaceuticals in a $2.1 billion deal. |
The Motley Fool
January 5, 2004
Alyce Lomax |
Side Effects at Lilly? Growing profits, with earnings pains. |
The Motley Fool
November 24, 2010
Brian Orelli |
A Manly FDA Approval Eli Lilly has something to be thankful for this week; the Food and Drug Administration approved Axiron, its testosterone replacement therapy. |
The Motley Fool
May 27, 2009
Brian Orelli |
A Wrinkle in the Botox Plan The FDA turns down Allergan's label expansion, but it wasn't all bad news. |
The Motley Fool
November 30, 2009
Brian Orelli |
Anxious No Longer Eli Lilly adds another approval onto Cymbalta. |
Chemistry World
April 29, 2014
Phillip Broadwith |
Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time. |
The Motley Fool
March 2, 2011
Susmita Chatterjee |
How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others? |
The Motley Fool
January 15, 2009
Robert Steyer |
For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move? |
The Motley Fool
August 20, 2010
Brian Orelli |
Depression Is Painful. Advisory Panels More So. Eli Lilly's Cymbalta has a rough time in from of the panel of experts. |
Chemistry World
November 27, 2015
Anthony King |
Pfizer and Allergan agree mega-merger The deal is being positioned as Irish-based Allergan taking over Pfizer, with the merged entity resident in Ireland for tax purposes. |
BusinessWeek
October 13, 2003
Arlene Weintraub |
He Bet on Botox -- And Won David Pyott transformed sleepy Allergan. Where is he taking its blockbuster drug? |
Chemistry World
January 25, 2013
Andrew Turley |
Allergan buys MAP for $958m Allergan, best known as the company behind Botox (onabotulinumtoxin A) injections, has agreed to buy US drug maker MAP Pharmaceuticals for $958 million |
CRM
February 2003
David Myron |
Support Gets a Face-Lift Allergan was able to automate the routing of 80 percent of all inbound, Web-generated emails, based on the business rules the company put in place. |
The Motley Fool
October 18, 2011
John Grgurich |
3 Stocks for Good Skin and Great Profits Find out which cosmetic company is prepared to make the most of a new skin care product trend. |
The Motley Fool
January 31, 2007
Brian Lawler |
No Earnings Face-Lift Needed For Allergan The ophthalmic and plastic surgery product developer has made many investors rich, and it's not stopping now. |
The Motley Fool
November 22, 2006
Brian Lawler |
Implant Approval Gives Allergan a Lift The return of silicone breast implants continues. Shares of Allergan, best known for its Botox wrinkle treatment, were up nearly 8% on the news. |
CIO
December 14, 2010
Kim S. Nash |
How Botox Battles Compliance Wrinkles A BPM overhaul saved the day after legal issues complicated compliance at Botox-maker Allergan. |
The Motley Fool
May 6, 2009
Robert Steyer |
Getting Ahead by Getting Rid of Wrinkles Medicis gets the FDA OK for an anti-wrinkle product as the market for Botox and other cosmetic skin drugs sags. |
The Motley Fool
December 15, 2003
Alyce Lomax |
No Wrinkles for Medicis Medicis Pharmaceuticals announced that the FDA has approved its injectable wrinkle-filling gel, Restylane. Allergan's Botox has found a new competitor in the fountain-of-youth market. |
BusinessWeek
December 25, 2006
Palmeri & Weintraub |
Silicone Goes Subtle Allergan's campaign relies on friendly persuasion. |
The Motley Fool
July 30, 2009
Alyce Lomax |
A Lovelier Bare Escentuals? The mineral makeup company is less risky, but not risk-free. |
The Motley Fool
March 3, 2009
Brian Orelli |
Pfizer Eyes Generic Growth Two partnerships in one day? Oh my! |
The Motley Fool
September 20, 2007
Brian Lawler |
Allergan's Overactive Acquisition Specialty pharma Allergan announced yesterday that it is acquiring privately held Esprit Pharma for $370 million in an all-cash transaction. Investors, take note. |
BusinessWeek
March 25, 2010
Elizabeth Lopatto |
And Now, Gastric Surgery for Kids Allergan wants to market its Lap-Band implants for younger obese patients, but some doctors are balking |
The Motley Fool
February 8, 2011
Esterhuizen & Sellitti |
Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch. |
